Special Issue "Non-coding RNA and Cancer: New Treatment Opportunities and Impact on Metastasis and Therapy Resistance"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3566
Interests: novel Ru-based nanosystems for cancer therapy
Interests: cancer; cell death pathways; miRNA; long non-coding RNA; cell signaling; apoptosis; autophagy; nanotechnology; drug delivery; chemotherapy; combination therapy; target-therapy; immunotherapy; biomarkers
Special Issues, Collections and Topics in MDPI journals
The advent of emerging molecular and genetic omics technologies has made a powerful contribution to understanding the biochemical alterations behind cancer development and progression. Cancer-associated specific molecular dysregulation is largely supported by noncoding RNAs (ncRNA), whose expression is, in turn, frequently altered in pathologic conditions as a result of mutations or copy number variations in non-coding DNA regions. Based on their size, functional ncRNA molecules are analytically classified as long ncRNAs (lncRNAs, >200 nt), and small ncRNAs (sncRNAs, 18–200 nt). The first represent the largest class of non-coding transcripts acting as chromatin, transcriptional and post-transcriptional regulators, as well as in protein and RNA scaffolding. sncRNAs include, but are not limited to, microRNA (miRNA), endogenous small interfering RNAs (endo-siRNAs), PIWI-associated small RNAs (piRNAs) and small nucleolarRNAs (snoRNAs), acting as essential transcriptional and translational regulators. Due to their aberrant expression in human neoplasms, they can behave as either oncogenes or tumor suppressors in a tissue-specific manner, thus providing novel therapeutic opportunities to be translated into clinics for successful cancer treatment. Among the cancer-related processes controlled by ncRNAs, molecular regulatory networks governing metastasis are frequently investigated for the possible diagnostic and therapeutic applications of these molecules. Furthermore, the involvement of ncRNAs in either promoting or hindering multidrug resistance in certain cancer types is notable.
This Special Issue will explore the latest advances in ncRNA research, focusing on the regulatory function of ncRNAs in cancer-related processes with particular attention toward their advantages of commitment in metastatic events or drug resistance, as well as to their application as therapeutic agents.
Dr. Carlo Irace
Dr. Gabriella Misso
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapy resistance
- cancer treatment
- cell death